Market evolution: Surgical sutures (CN 300610) — 2015–2025

Introduction

This report examines the evolution of EU external trade in products under Combined Nomenclature code 300610, which covers sterile surgical catgut, suture materials, tissue adhesives for wound closure, absorbable haemostatics, and surgical adhesion barriers. Over the 2015–2025 period, the EU has consolidated its position as a strong net exporter of these medical products. Total export value grew by 86%, reaching nearly €1.3 billion in 2025, while imports rose more modestly by 37% to approximately €818 million. The EU's trade surplus expanded from €100 million to €479 million over the period. Three major dynamics stand out: a structural shift toward higher-value exports, a significant reorientation of trade partners — particularly the surge in trade with the United States and Mexico — and a striking growth of the surgical catgut sub-segment (30061010) in both imports and exports.

1. A Widening Surplus Fueled by Price Appreciation Rather Than Volume Alone

EU exports have grown far faster in value than in volume

Between 2015 and 2025, EU exports of CN 300610 products rose from approximately €698 million to €1,297 million (+86.0% in value), while export volumes increased from 2,879 tonnes to 3,413 tonnes (+18.5%). This divergence signals that unit export prices climbed by 56.9%, from around €242,000 per tonne to €380,000 per tonne. The EU's competitive advantage in this sector is thus increasingly rooted in higher-value-added products rather than sheer volume expansion.

Import growth has been more moderate and volume-driven

On the import side, the EU's intake grew from €598 million to €818 million (+36.9%) and from 2,574 tonnes to 3,144 tonnes (+22.2%). Import unit prices rose only 12.1% over the full period, from €232,000/t to €260,000/t. The contrast with export price dynamics is notable: while the EU is paying relatively stable prices for incoming goods, it is commanding increasingly higher prices for its exports.

The trade surplus has nearly quintupled

The net import reliance indicator — which is negative when a region is a net exporter — deepened from −71.7% to −210.4%, confirming that the EU's export surplus has grown substantially faster than its import needs. The EU's export propensity reached 181% in 2025, meaning the EU exported far more in value than its domestic production alone would suggest — indicative of re-export activity and strong intra-EU consolidation of manufacturing.

Domestic production has more than doubled

EU production value rose from €321 million to €697 million (+117.4%), providing the manufacturing base that underpins the export boom. However, since export value (€1,297M) far exceeds reported production value, a significant share of EU exports likely reflects trade in goods manufactured elsewhere but distributed through EU-based hubs, particularly Belgium and the Netherlands.

2. Geographic Reorientation: The United States, Mexico, and Shifting Partner Dynamics

The United States has become the EU's dominant trade partner on both sides

The most striking geographic shift has been the exponential growth in EU–US trade:

EU exports to the US surged from €80 million to €369 million, making the US the single largest export destination by 2025, overtaking the United Kingdom. Meanwhile, US-origin imports grew only modestly. This dramatic shift may reflect the consolidation of global medical device supply chains through EU-based intermediaries, as well as growing demand in the US healthcare market for high-end European suture and barrier products.

Mexico has emerged as a major new import source

EU imports from Mexico jumped from €7.2 million to €245.9 million (+3,294%), making Mexico the second-largest import origin by 2025 after the United States. This surge is likely linked to the expansion of manufacturing capacity by multinational medical device companies in Mexico, which serves as a nearshoring platform for the North American market and increasingly for global distribution, including into the EU.

The United Kingdom's role has declined on the import side

EU imports from the UK fell from €103.6 million to €35.1 million (−66.1%), a decline almost certainly linked to Brexit. The UK's departure from the EU customs union and single market introduced new trade frictions. However, EU exports to the UK remained robust, rising from €134.9 million to €168.1 million (+24.6%), suggesting continued UK demand for EU-manufactured surgical products despite the new regulatory and customs barriers.

EU export concentration has increased

The export-side Herfindahl-Hirschman Index (HHI) for partner concentration rose from 732 to 1,170, reflecting the growing weight of a small number of large partners — particularly the United States. The import-side HHI declined slightly from 3,471 to 3,169, indicating a modest diversification of import sources, even as the US and Mexico have gained ground. The volatility analysis confirms that trade with emerging partners such as Mexico (CV 0.75) and India (CV 0.61) has been considerably more volatile than with established partners like the United States (CV 0.14 on the import side).

3. The Catgut Sub-Segment Has Driven the Most Dramatic Shifts Within CN 300610

CN 300610 covers three distinct sub-segments

The product heading 300610 bundles three sub-categories:

• 30061090: Sterile suture materials, haemostatics, tissue adhesives, laminaria — the dominant segment by volume
• 30061010: Sterile surgical catgut — traditionally smaller but rapidly growing
• 30061030: Sterile surgical/dental adhesion barriers — the smallest segment, highly volatile

The catgut sub-segment (30061010) has undergone a remarkable transformation

The most dramatic evolution within CN 300610 has occurred in surgical catgut:

Catgut imports have surged both in volume and value, suggesting growing EU demand for this raw or semi-processed biomaterial. The export price explosion — from €148,000/t to over €1,000,000/t — indicates that the EU is increasingly exporting finished, high-value catgut-based surgical products rather than raw materials, processing imported catgut into premium goods.

The main suture segment (30061090) remains dominant but shows divergent trends

Sub-heading 30061090 — covering the bulk of suture materials, haemostatics, and tissue adhesives — remains the largest segment. However, its trajectory reveals a notable divergence:

While exports of suture materials grew strongly in both value and price, imports actually declined. This pattern, combined with the rise in EU production value, suggests that the EU has progressively substituted foreign supply with domestic manufacturing in this core segment.

Adhesion barriers (30061030) remain small but highly volatile

The adhesion barrier segment (30061030) is the smallest in volume but has shown extreme price volatility. Import unit prices surged from €72,479/t to €735,815/t over the period, while import volumes collapsed from 298 tonnes to 45 tonnes. On the export side, adhesion barrier prices also climbed sharply to €301,441/t. These dynamics suggest a shift toward high-value, low-volume trade in an increasingly specialised product category.

Belgium and the Netherlands dominate EU trade flows

Among EU Member States, Belgium is by far the largest trader, accounting for €607 million in exports (47% of the EU total) and €545 million in imports (67%) in 2025. The Netherlands has emerged as the second-largest exporter (€170M, up from €10M in 2015, +1,671%), and the second-largest importer (€118M, up from €16M, +659%). Both countries serve as major logistics and distribution hubs for global pharmaceutical and medical device companies, which explains their outsized trade figures relative to domestic production.

Conclusion

Over 2015–2025, the EU has significantly strengthened its position as a net exporter of surgical suture and wound closure products (CN 300610). The trade surplus grew nearly fivefold to €479 million, driven primarily by value appreciation in exports (+57% in unit prices) rather than volume expansion alone. The geographic landscape of trade has been reshaped: the United States has become the EU's paramount bilateral partner on both the export and import sides, Mexico has emerged as a major new import source likely reflecting nearshoring trends, and the United Kingdom's role as an import supplier has diminished post-Brexit. Within the product mix, the surgical catgut sub-segment (30061010) has experienced the most dramatic shifts, with export prices exceeding €1 million per tonne by 2025 — suggesting the EU is capturing increasing value through advanced processing and finishing of biomaterials. While the EU's strong export orientation signals competitiveness, the growing concentration of exports toward a small number of partners — and the volatility observed with emerging trade routes — warrants continued attention to supply chain resilience in this strategically important medical sector.